Immutep Limited (ASX:IMM) Reports Promising Clinical Data
Positive Clinical Results
Immutep Limited (ASX: IMM) has released encouraging clinical data from its TACTI-003 trial, demonstrating effective outcomes in patients with advanced head and neck squamous cell carcinoma (HNSCC). The Phase IIb trial evaluated eftilagimod alpha (efti) combined with pembrolizumab (KEYTRUDA®) in patients with negative PD-L1 expression, a group known for limited treatment options.
The data presented at the ESMO Immuno-Oncology Annual Congress 2024 indicates a 12-month overall survival (OS) rate of 67%, with the median OS yet to be reached. Progression-free survival (PFS) was reported at 5.8 months, and durability showcased a median duration of response (DOR) at 9.3 months. The objective response rate (ORR) stood at 35.5%, further illustrating the treatment’s potential.
Well-Tolerated Treatment
Immutep’s combination therapy continues to be well tolerated, with no new safety signals reported. The complete response rates increased to 12.9% and 16.1% using RECIST 1.1 and iRECIST metrics, respectively.
Marc Voigt, CEO of Immutep, expressed optimism about these results, stating, “We believe this data is an encouraging step in the right direction towards potentially bringing a new approach to this underserved population.” These findings provide hope for the roughly 20% of HNSCC patients who have few therapeutic options.
Next Steps
Immutep plans to maintain follow-up on the data from TACTI-003 and will engage regulatory bodies regarding potential future developments. The full poster from the ESMO presentation will be accessible on Immutep’s website for further details.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.